| Anticancer Fund

Omics-driven drug repurposing in rare cancers

Pantziarka, P. & Meheus, L. (2018). Omics-driven drug repurposing as a source of innovative therapies in rare cancers. Expert Opinion on Orphan Drugs, 6(9), 513-517. doi:10.1080/21678707.2018.1500690

Tue, 07/24/2018 - 12:00

Zoom in: ACF for patients

Fri, 07/20/2018 - 12:00

Zoom in: ACF for patients

Mon, 07/16/2018 - 12:00

Guy Buyens becomes new medical director of the Anticancer Fund

Wed, 07/04/2018 - 12:00

New uses for old drugs

Pantziarka, P., Pirmohamed, M., & Mirza, N. (2018). New uses for old drugs: Low cost generics are an untapped source of therapeutic innovation. BMJ, 361, k2701. doi:10.1136/bmj.k2701

Tue, 06/26/2018 - 12:00

Propranolol and breast cancer—a work in progress

Pantziarka, P., Bryan, B. A., Crispino, S., & Dickerson, E. B. (2018). Propranolol and breast cancer-a work in progress. Ecancermedicalscience, 12, ed82. doi:10.3332/ecancer.2018.ed82

Mon, 06/18/2018 - 12:00

Uppsala Health Summit 2018: Care for Cancer

14-15 June 2018 | Uppsala Castle, Sweden

Thu, 06/14/2018 - 12:00

Drug Repurposing as a Source of Innovative Therapies in Pancreatic Cancer

presented on EPC 2018 by our colleague Ilse Rooman

Thu, 06/14/2018 - 12:00